Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease

Wyeth

Status and phase: Terminated; Phase 2

Conditions: Arrhythmia

Treatments: Drug: 0.9% Sodium Chloride, USP; Drug: GAP-486 (ZP-123)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00137332

3163K1-202

Details and patient eligibility

About

The purpose of this study is to learn the effects of a test drug on heart rhythms, which may become life-threatening if left untreated, and to provide data to see if the drug is well tolerated and safe.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with or without ICDs (implantable cardioverter defibrillators)
• Patients undergoing an electrophysiology study for evaluation of ventricular rhythm
• Patients with a history of heart disease

Exclusion criteria

• Patients with uncontrolled blood pressure
• Patients with certain cardiac risk factors
• Patients with significant kidney or liver problems

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind